Mediantechn (ALMDT) - Total Liabilities
Based on the latest financial reports, Mediantechn (ALMDT) has total liabilities worth €71.02 Million EUR (≈ $83.03 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mediantechn - Total Liabilities Trend (2008–2025)
This chart illustrates how Mediantechn's total liabilities have evolved over time, based on quarterly financial data. See Mediantechn (ALMDT) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Mediantechn Competitors by Total Liabilities
The table below lists competitors of Mediantechn ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GuocoLand (Malaysia) Bhd
KLSE:1503
|
Malaysia | RM874.57 Million |
|
inTest Corporation
NYSE MKT:INTT
|
USA | $47.69 Million |
|
RF Industries Ltd
NASDAQ:RFIL
|
USA | $34.79 Million |
|
Exacompta Clairefontaine
PA:ALEXA
|
France | €367.69 Million |
|
Li-FT Power Ltd.
F:WS0
|
Germany | €23.25 Million |
|
Associated Alcohols & Breweries Ltd.
NSE:ASALCBR
|
India | Rs1.61 Billion |
|
Osisko Metals Inc
V:OM
|
Canada | CA$83.54 Million |
|
INKEVERSE GROUP DL-001
F:5IK
|
Germany | €735.62 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Mediantechn's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Mediantechn market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.98 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mediantechn's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mediantechn (2008–2025)
The table below shows the annual total liabilities of Mediantechn from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €71.02 Million ≈ $83.03 Million |
+21.74% |
| 2024-12-31 | €58.34 Million ≈ $68.20 Million |
+26.20% |
| 2023-12-31 | €46.23 Million ≈ $54.05 Million |
+10.05% |
| 2022-12-31 | €42.01 Million ≈ $49.11 Million |
-5.50% |
| 2021-12-31 | €44.45 Million ≈ $51.97 Million |
+21.29% |
| 2020-12-31 | €36.65 Million ≈ $42.84 Million |
+146.94% |
| 2019-12-31 | €14.84 Million ≈ $17.35 Million |
+63.89% |
| 2018-12-31 | €9.05 Million ≈ $10.59 Million |
-1.65% |
| 2017-12-31 | €9.21 Million ≈ $10.76 Million |
+17.78% |
| 2016-12-31 | €7.82 Million ≈ $9.14 Million |
+6.99% |
| 2015-12-31 | €7.31 Million ≈ $8.54 Million |
+78.46% |
| 2014-12-31 | €4.09 Million ≈ $4.79 Million |
+880.23% |
| 2013-12-31 | €417.66K ≈ $488.29K |
-14.49% |
| 2012-12-31 | €488.41K ≈ $571.00K |
-90.97% |
| 2011-12-31 | €5.41 Million ≈ $6.33 Million |
-26.18% |
| 2010-12-31 | €7.33 Million ≈ $8.57 Million |
+70.29% |
| 2009-12-31 | €4.30 Million ≈ $5.03 Million |
+194.86% |
| 2008-12-31 | €1.46 Million ≈ $1.71 Million |
-- |
About Mediantechn
Median Technologies SA engages in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development with operations spanning in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iSee for imaging services in clinical trials; eyonis for non-invasive diagnos… Read more